Amyloid-beta accumulation in aggregates is thought to be the leading cause of Alzheimer's disease. Despite the many advances in the field, it is still challenging to diagnose Alzheimer's in the early stages of the disease. Therefore, there is a need to find reliable biomarkers that can be easily detected from the very onset of the disease. Here, a new method based on proteomic profiling is used to identify serum proteins related to amyloid-beta plaque formation to be used as biomarkers. The results show that there are effectively amyloid beta-related serum proteins. Among them, a considerable percentage are unique for amyloid plaque particles in Alzheimer's serum compared to cholesterol, alpha-synuclein and tau plaque particles. Additionally, some of them were also able to form amyloid-beta plaques in vitro. Overall, the researchers show a new, potentially non-invasive, method to easily detect proteins and identify proteins related to amyloid-beta plaque formation to be used as biomarkers.
Plaque array method and proteomics-based identification of biomarkers from Alzheimer's disease serum
The IE from MS no longer understands current scripting languages, the latest main version (version 11) is from 2013 and has not been further developed since 2015.
Our recommendation: Use only the latest versions of modern browsers, for example Google Chrome, Mozilla Firefox or Microsofrt Edge, because only this guarantees you sufficient protection against infections and the correct display of websites!